Transcript

[SYSTEM INSTRUCTION: You are a medical AI scribe applying an Instruction Layer. 1. Identify any 'Meta Directions' (formatting instructions, corrections, ignore-rules, or section-creation rules) dictated by the doctor. 2. Do NOT treat Meta Directions as clinical facts. Instead, use them as strict rules to shape the final note. 3. Apply formatting instructions (e.g., bullet points, conciseness). 4. Apply correction instructions (e.g., overriding a pain score or symptom). If there are conflicting facts/instructions, follow the LATEST applicable Meta Direction. 5. Apply ignore instructions (e.g., omit specific brand names). 6. Move information to the section explicitly requested. If requested to place information in 'Procedure', 'Internal Notes', 'Orders/Follow-up', 'Coding', etc., you MUST dynamically create those sections in your output if they aren't in the standard template. 7. Do not invent unsupported clinical information. Preserve existing normal dictation behavior. 8. Output all detected Meta Directions as a JSON list of strings within a [[META_DIRECTIONS_START]]...[[META_DIRECTIONS_END]] block at the very end of your response.
9. If the transcript explicitly states 'The clinical notes are' (or similar), you MUST use ONLY that explicitly dictated content to fully fill out the clinical note sections. Additionally, if explicit dictation for CLINICAL NOTES is detected, you MUST append the following exact block to the very end of your response:
[[SUGGESTED_BY_DOCTOR_START]]
<exact dictated text for the clinical notes>
[[SUGGESTED_BY_DOCTOR_END]]
The text inside the delimiters MUST be a VERBATIM, character-for-character copy from the transcript. Do NOT fix typos, do NOT reformat, and do NOT correct medical terms. Do NOT output 'Suggested by Doctor:' in the main text. Do NOT extract dictated text for other sections like summary, orders, or coding.]

[TRANSCRIPT]
=== NIO FULL WORKFLOW TEST TRANSCRIPT ===
Purpose: single synthetic encounter designed to touch every core engine -- clinical
notes, prescriptions, prior authorization, medical coding, visit summary, referral,
appointment scheduling/follow-up, patient check-in, longitudinal patient context,
and AI clinical assistance. All patient data below is fictional.

--- SECTION 1: CHECK-IN / INTAKE ---

Front desk check-in note: Patient Robert Chen, date of birth September 2, 1965,
checking in for a 2:30pm follow-up visit. Insurance on file is Pacific Blue Cross,
member ID PBC7734210, group 8842. Insurance card has been re-verified today, no
changes since last visit. Copay of 25 dollars collected. Patient confirms address
and phone number are unchanged. Patient completed pre-visit questionnaire noting
increased fatigue and joint pain over past month.

--- SECTION 2: LONGITUDINAL CONTEXT / VISIT HISTORY ---

This is patient's third visit this year. Prior visit February 12 diagnosed early
rheumatoid arthritis, started on methotrexate 15 milligrams weekly. Visit May 20
showed inadequate response, ESR and CRP still elevated, methotrexate increased to
20 milligrams weekly. Today's visit is a re-evaluation after 4 months on increased
dose.

--- SECTION 3: DICTATED ENCOUNTER NOTE ---

Chief complaint: continued joint pain and morning stiffness despite methotrexate
therapy, now with new fatigue.

History of present illness: patient reports morning stiffness lasting over 90
minutes, bilateral symmetric pain in wrists, MCPs, and knees, rated 6 out of 10.
Fatigue has worsened over the past month, patient reports difficulty completing
normal work day. No fevers, no rash, no chest pain, no shortness of breath.
Compliant with methotrexate and folic acid.

Review of systems otherwise negative.

Exam: bilateral wrist swelling and tenderness, MCP joints 2 and 3 swollen
bilaterally, decreased grip strength, mild synovitis at both knees, no effusion.
Skin exam normal, no nodules. Vitals stable, blood pressure 128 over 82, heart
rate 78, weight 165 pounds.

Labs reviewed from this morning: ESR 42, CRP 18, still elevated despite therapy.
CBC and liver function panel within normal limits.

--- SECTION 4: ASSESSMENT AND DIAGNOSIS CODING ---

Assessment: rheumatoid arthritis, seropositive, moderate disease activity,
inadequate response to methotrexate monotherapy. Diagnosis code M05.79, rheumatoid
arthritis with rheumatoid factor of multiple sites. Secondary diagnosis fatigue,
code R53.83.

--- SECTION 5: PRESCRIPTIONS ---

Plan includes continuing methotrexate 20 milligrams weekly and folic acid 1
milligram daily. Given inadequate response after dose escalation, starting
adalimumab, brand name Humira, 40 milligrams subcutaneous injection every other
week. Also prescribing prednisone 10 milligrams daily tapering over two weeks as
bridge therapy while biologic takes effect.

--- SECTION 6: PRIOR AUTHORIZATION TRIGGER ---

Adalimumab is a specialty biologic and will require prior authorization from
Pacific Blue Cross before dispensing. Documentation to support: diagnosis M05.79,
failed first-line methotrexate monotherapy at adequate dose of 20 milligrams
weekly for over 3 months, elevated inflammatory markers ESR 42 and CRP 18
confirming active disease, physical exam findings of active synovitis in multiple
joints. This should satisfy standard step-therapy criteria for biologic approval
in rheumatoid arthritis.

--- SECTION 7: PROCEDURE / ADDITIONAL CODING ---

Ordering repeat ESR and CRP in 6 weeks to assess biologic response, CPT codes
85652 and 86140. Also ordering baseline tuberculosis screening, QuantiFERON gold
test, CPT 86480, required prior to starting adalimumab per standard biologic
initiation protocol. Administered today: injection training and first dose
administration, CPT 96372.

--- SECTION 8: REFERRAL ---

Referring patient to ophthalmology for baseline eye exam given long-term
corticosteroid and biologic use, and to physical therapy for hand and grip
strengthening exercises twice weekly for 6 weeks.

--- SECTION 9: AI CLINICAL ASSISTANCE PROMPT ---

Clinician query to AI assistant: "Given inadequate response to methotrexate
monotherapy at 20 milligrams weekly with elevated ESR and CRP, is adalimumab an
appropriate next step, and what baseline screening is standard before starting a
TNF inhibitor in this patient?" Expect AI assistance module to confirm step-therapy
appropriateness, flag baseline screening requirements (TB test, hepatitis B and C
panel, chest x-ray if indicated), and note contraindication screening for active
infection or heart failure.

--- SECTION 10: VISIT SUMMARY / PATIENT-FACING NOTE ---

Summarize for patient: your rheumatoid arthritis is still active despite your
current medication, so we are adding a new medication called Humira to better
control the inflammation. Continue your current methotrexate and folic acid. Start
a short course of prednisone to help symptoms while the new medication takes
effect. We are sending a referral to an eye doctor and to physical therapy. You
will need a TB test and blood work before starting Humira, and insurance approval
may take a few days, our office will contact you once authorized.

--- SECTION 11: FOLLOW-UP / SCHEDULING ---

Plan: follow-up appointment in 6 weeks to reassess disease activity, repeat labs at
that visit. Front desk to schedule patient for follow-up on or around November 3,
and to call patient once prior authorization for adalimumab is approved to arrange
pharmacy pickup and injection teaching session. Patient also needs reminder call in
2 weeks to confirm TB test and referral appointments were completed.

=== END TEST TRANSCRIPT ===